Revolutionizing Mental Health: At-Home Ketamine-Assisted Therapy
In the hidden struggles of our lives, millions grapple silently with depression and anxiety, the leading causes of disability among those aged 15–44 in the United States.
According to the National Alliance of Mental Health (NAMH),
1,405,000 adults in Georgia have a mental health condition.
As more individuals seek help, clinical resources face challenges keeping up with the diverse demand. Not all of the conventional therapies resonate or fit with everyone, highlighting the need for groundbreaking innovations.
Enter a promising solution: At-Home Ketamine Assisted Therapy (KAT).
Ground-breaking Advancements for Those Suffering from Depression and Anxiety
Depression and anxiety, powerful adversaries, can cast a shadow even on the brightest days. While traditional therapies play a pivotal role, they often fall short of meeting the diverse needs of those they aim to help. Understanding this gap, medical researchers and practitioners have embarked on a journey to explore uncharted territories, offering new rays of hope to those who have exhausted conventional avenues.
Ketamine assisted therapy or KAT, a novel approach that marries the potency of ketamine therapy, with traditional talk therapy, has risen in popularity for mental health conditions like depression and anxiety.
Traditionally, the administration of ketamine required the expertise of trained medical professionals through intravenous or intramuscular routes. However, the associated costs and limited accessibility of these methods spurred a revolutionary concept: at-home therapies.
A groundbreaking study conducted by Hull et al. brought to light the real-world impact of ketamine assisted therapy. Encompassing 1247 patients with moderate–severe depression and severe anxiety, this prospective trial unfolded over four weeks. These patients embarked on a series of weekly KAT sessions utilizing sublingual ketamine administration — placing a tablet or troche under the tongue for absorption — and facilitated through communication with telehealth providers. The results unveiled that an astonishing 62.8% experienced a remarkable 50% or greater improvement in depression symptoms, mirrored by 62.9% experiencing a similar positive shift in anxiety symptoms. These figures represent more than just percentages; they symbolize renewed hope for those who have long battled in the shadows.
What does this mean?
This paradigm shift empowers patients to actively participate in their wellness journey. KAT exists with the goal of having the potential therapeutic benefits of ketamine easily accessible to work with talk therapy.
Georgia’s Experts in Ketamine
The power of compounded ketamine, in forms that can be easily administered at home, paired with talk therapy may be the right fit for many patients. Morgan Compounding Pharmacy works with top mental health care providers in Georgia by providing custom compounded ketamine for patients in KAT programs.
Most Common Ketamine Dosage Forms Used for Depression–Anxiety–OCD, PTSD, Pain, and Ketamine Assisted Therapy
This innovative, at-home approach simultaneously reduces costs, increases accessibility, and provides another option for patients with mental health issues.
Georgia’s ketamine experts at Morgan Compounding Pharmacy are at the forefront of this revolution in utilizing ketamine assisted therapy for anxiety and depression. Through dedication and innovation, we rewrite the narrative of addressing mental health conditions, offering a brighter and more accessible future — one personalized prescription at a time.
In a healthcare landscape marked by challenges in accessibility, availability, and affordability, Morgan Compounding Pharmacy emerge as a pivotal player towards better outcomes. Our local, family-owned compounding pharmacy stands as a beacon of support for Georgia’s patients and practitioners, crafting tailored solutions and groundbreaking therapies.
Here to help.
Contact Morgan Compounding Pharmacy today with questions on how we may help you to address your patients’ needs today.
Zarate CA, Singh JB, Carlson PJ, et al. A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression. Arch Gen Psychiatry. 2006;63(8):856–864. doi:10.1001/archpsyc.63.8.856